Quest Diagnostics (DGX) Cash & Current Investments (2009 - 2026)

Quest Diagnostics (DGX) has 18 years of Cash & Current Investments data on file, last reported at $393.0 million in Q1 2026.

• Quarterly Cash & Current Investments rose 109.04% year-over-year to $393.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $393.0 million (up 109.04% YoY) and the FY2025 annual result came in at $420.0 million, down 23.5% from the prior year.
• Cash & Current Investments slipped to $393.0 million in Q1 2026 per DGX's latest filing, from $420.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $790.0 million in Q2 2022, with the low at $126.0 million in Q2 2023.
• Average Cash & Current Investments over 5 years is $438.6 million, with a median of $420.0 million recorded in 2025.
• Year-over-year, Cash & Current Investments sank 84.05% in 2023 and surged 434.27% in 2024.
• Quest Diagnostics' Cash & Current Investments stood at $315.0 million in 2022, then jumped by 117.78% to $686.0 million in 2023, then decreased by 19.97% to $549.0 million in 2024, then dropped by 23.5% to $420.0 million in 2025, then slipped by 6.43% to $393.0 million in 2026.
• Business Quant data shows DGX's Cash & Current Investments at $393.0 million in Q1 2026, $420.0 million in Q4 2025, and $432.0 million in Q3 2025.